Gene-toxicant link to Parkinson's disease. by unknown
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Brian J. Balin, an associate professor at the
Philadelphia College of Osteopathic
Medicine in Pennsylvania, and Alan P.
Hudson, an associate professor in the
department ofmicrobiology and immunol-
ogy at Wayne State University School of
Medicine in Detroit, Michigan, led what
may prove to be a huge step forwarding in
understanding Alzheimer's. Says Balin,
"We don't have a definite cause yet, butwe
definitely have a potential cause or risk fac-
tor forthe disease."
C. pneumoniae is the cousin of C. tra-
chomatis, which causes both the sexually
transmitted infection commonly known as
chlamydia and trachoma, a form ofblind-
ness. C. pneumoniae is a pervasive bacteri-
um, appearing in 40-70% of adults.
Unlike most other bacteria, C.
pneumoniae can only live inside a
cell and draws its energy from
the cell's supply of adenosine
triphosphate. The bacterium is
spread through sneezing and
coughing, and causes diseases
such as sinusitis and bronchitis.
In studying the relationship
between C. pneumoniae and late-
onset Alzheimer's, Balin and
Hudson used postmortem sam-
ples from various regions of the
brains of patients both with and
without Alzheimer's. From each
sample, the scientists prepared
samples of nucleic acid, which
were screened by polymerase
chain reaction assay for the pres-
ence oftwo C.pneumoniaemarker
genes. Analyses showed that sam-
ples from 17 ofthe 19 brains with
Alzheimer's tested positive for the bacteria,
while only 1 of 19 brain samples without
Alzheimer's testedpositive.
The C. pneumoniae cells were found to
be concentrated in the microglial and
astroglial cells. (The microglia function as
an immune system within the brain, gener-
ating severe inflammation when infected,
while the astroglia promote neuronal cell
maintenance and growth.) The organism
was also found to be concentrated in brain
regions marked by neuropathologies char-
acteristic ofAlzheimer's, such as neurofib-
rillary tangles, composed ofthe cytoskeletal
proteins ofdamaged neurons, and neuritic
senile plaques, caused by the accumulation
of the peptide P-amyloid-believed by
some scientists to be secreted by the
astroglia.
Balin and Hudson think the deposi-
tion and processing of ,B-amyloid may
begin after an initial infection with C.
pneumoniae. "Where you have certain
types ofpathology, that's where you have
accumulation ofthe organism," says Balin.
This raises the possibility that the damag-
ing plaques and tangles may form in
response to infection with C. pneumoniae.
Balin also believes the organism may live
in people's cells for decades, causing a
slow, chronic immune response. By hiding
out in the body, he posits, the bacterium
escapes surveillance as a foreign body.
There maybe additional factors acting in
relationshipwith C.pneumoniae. "Ifeveryone
gets C. pneumoniae, why doesn't everyone
also get Alzheimer's disease?" asks Hudson.
'There are unidentified genetic factors work-
inginrelationshipwith C.pneumoniae." One
possible partner is apolipoprotein E, a serum
protein used in lipid transport. Each person's
DNA contains some combination oftwo of
This is your brain on pesticides? New research suggests exposure to
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five different alleles of apolipoprotein E;
while the APOE4allele occurs in 13-15%
ofthegeneral population, itturns up in 60%
ofAlzheimer's patients. Hudson and Balin
think APOE4may act in conjunction with
C. pneumoniae infection to cause
Alzheimer's. Says Balim, "We have a realistic
mechanism for allowing the organism to
entercelis incertainpeople."
The scientists also performed electron-
and immunoelectron-microscopic studies
on tissue samples from both Alzheimer's
and non-Alzheimer's brains. These studies
also identified C pneumoniae organisms in
the Alzheimer's samples but not in the
non-Alzheimer's samples. Culture studies
ofa subset ofAlzheimer's brain tissues for
C. pneumoniae were strongly positive,
while identical analyses ofnon-Alzheimer's
brain tissues were negative.
One ofthe next steps for the scientists
is to investigate how C. pneumoniae infil-
trates the nervous system. Balin plans to
examine postautopsy brain samples to
determine the earliest stages of late-onset
Alzheimer's and identify whether the
organism is present in those stages. Other
future projects include a cell culture study
to demonstrate which specific cellular
mediators are turned on by the C. pneumo-
niaeorganism, and developing methods for
diagnosing C. pneumoniae infection. The
findings of this research could result in
clinical trials ofantibiotics and antiinflam-
matory agents to treat Alzheimer's in the
near future. Says Balin, "Ifwe can block
the stimulus for inflammation and inflam-
mation itself, we may be able to prevent
damage." At the least, says Hudson, dam-
age could be postponed orameliorated.
Gene-Toxicant Link to
Parkinson's Disease
The combination ofpesticide expo-
sure and a particular genetic trait
may increase the risk that people
with Parkinson's disease will devel-
op dementia. That's the condusion
of a preliminary study conducted
by researchers at the University of
Kansas Medical Center in Kansas
City, Barrow Neurological Institute
in Phoenix, Arizona, and the
Veterans Affairs Puget Sound
Health Care System in Seattle,
Washington. The study, published
in the March-April 1998 issue of
Neuroepidemiology, looked for possi-
ble causes of the dementia that
occurs in about one-fifth of all
Parkinson's Datients.
Parkinson's disease is a brain
disorder that causes trembling, slow
movements, a rigid posture, and an unbal-
anced, shuffling walk. The subjects ofthis
study were 94 patients with Parkinson's
disease, 43 ofwhom had dementia and 51
ofwhom did not. The researchers looked
atvarious environmental, sociodemograph-
ic, and clinical variables, as well as three
suspected gene markers. As in previous
research, they found that lower educational
level, older age at disease onset, and greater
motor impairment were individual risk fac-
tors for dementia. For the first time, they
also showed that patients who had been
exposed to pesticides in the past and who
had a gene known as the CYP 2D629B+
allele were three times more likely to devel-
op dementia than patients who lacked this
combination offactors.
"This study was the first attempt in
Parkinson's disease to see ifwe could iden-
tify interactions between unique genetic
makeups and exposure to environmental
toxins," says coauthor Matthias Kurth,
director of clinical science for Axys
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Pharmaceuticals in LaJolla, California. For
purposes of the study, the researchers
defined pesticide exposure as pesticide use
for more than 20 days in any given year, a
level they say is based on typical use ofthe
chemicals in commercial grain farming.
The allele in question activates a series of
enzymes in the liver that metabolize and
detoxify chemicals that enter the body.
However, up to 10% ofCaucasians have a
mutant version of the allele, which results
in no activity of this enzyme system. The
hypothesis is that such people might be
particularly susceptible to environmental
toxicants because of their inability to
detoxify chemicals.
While provocative, this study does
have some important limitations. Its
case-control design is less than ideal for
studying risk factors in Parkinson's dis-
ease, because symptoms of the disease
may change over time. Thus, some ofthe
subjects in the no-dementia control
group may later develop dementia.
Another drawback is the study's reliance
on self-reports from dementia patients.
Yet another concern is "the absence of
predictive value for either pesticide expo-
sure or the allele taken alone," says Jean
Harry, a group leader in the
NIEHS Environmental Toxi-
cology Program. Only the inter-
action between these variables
was statistically significant. In
addition, Harry notes that the
study used "a crude estimate of
pesticide exposure." Still, she
says, the results offer interesting
data for further evaluation.
Clearly, the gene-toxicant
interaction still needs to be con-
firmed by further research, ideal-
ly a larger, prospective study of
Parkinson's-related dementia. Several pre-
vious studies found an association between
Parkinson's disease and pesticides, other
toxicants, and rural living, but so far no
specific pesticide or class ofenvironmental
toxicants has been definitively linked to
the disease. "Overall, past studies support
the notion that pesticide exposure is a risk
factor for Parkinson's disease, but only in
a subset of individuals," says Kurth. In
fact, he says, "Most Parkinson's patients
do not have a history of pesticide expo-
sure, and the recognition of Parkinson's
disease predates the development of these
compounds." The gene-toxicant interac-
tion is another tantalizing clue in the
quest for the causes of Parkinson's disease
in its various forms, but only time will tell
whether it is a true clue or a red herring.
5r K FJGenetic Toolbox
As the Human Genome Project steadily rolls forward, much of the information on
human chromosomes is being catalogued in digital databases such as GenBank, which
now contains well over 141 million base pairs' worth ofinformation on human DNA.
The problem facing scientists now is not so much how to gather genetic information,
but-rather how to take advantage ofthe data that have already been harvested. This is where
researchers such as Harold "Skip" Garner are trying to make a difference. With the help ofa
Hewlett-Packard supercomputer and theWorld WideWeb, Garner and his colleagues at the
University ofTexas Southwestern Medical Center in Dallas are gathering useful information
from GenBankand making itavailable to researchers across theglobe.
Especially interesting to scientists that studygenetically influenced diseases are the pieces
ofhuman DNA that tend to vary among individuals. Differences in these regions-called
polymorphisms-can be telltale signs that a person carries a genetic disease or is genetically
susceptible to getting a disease. Because GenBank contains manyduplicate bits ofDNAdata
that come from the same part ofthe samechromosome but from different individuals, analy-
sis ofthedatabasecanshowwherepolymorphisms tendto occur.
Gleaning the locations ofpolymorphisms from the data in GenBank is the purpose of
the Polymorphic Marker Predictions ofUbiquitous Simple Sequences, or POMPOUS, a
suite ofcomputer programsdesigned byGarnerandhiscolleagues. Thus far, POMPOUS has
found 13,261 polymorphic regions in the human genome. Information about these regions,
including their nudeotide sequences, is available on the Garner laboratory home page at
http://pompous.swmed.edu.
Bydickingthe POMPOUS linkon the Garnerhomepageand then
following the link named Analysis ofYour Sequence by POMPOUS
Server, researchers can'also make use ofthesupercomputer's eight proces-
sors and 0.5 gigabytes ofRAM to compare their own data to GenBank.
Not onlywill the computer find known polymorphic regions in the sup-
plied DNAsequence (up to 32,000 baseslong), itwill also return apairof
primers for each. Primers are unique DNA sequences used to isolate the
polymorphic region for further study. In a test of the software,
POMPOUS identified 33 polymorphic regions in a part of a human
chromosome implicated in breast and lung cancer. Twenty-two ofthese
wereshown to actuallyvaryin agroup of36 cancerpatients.
Other software tools for genetic researchers are also available from
the Garner site. These can be accessed by following the Computational
Biologylink on thehome page. One ofthesetools, GeneAlert, assists researcherswho are ana-
lyzing aknown sequenceofDNAusingthe National Centerfor BiotechnologyInformation's
BLAST programs. GeneAlert will automatically pare down the often exhaustive lists of
matching DNA sequences returned from such a search to only those that are relevant, for
instance, only those containing a certain keyword such as "human" or "carcinoma." Another
software tool available at this site is SIGNAL, aprogram that can be downloaded and used to
make comparisons between DNA and protein sequences. Other tools, induding a complex
and thorough genehuntingsystem, areplannedforinclusion on thesite in thefuture.
Another highlight ofthe Garner site is the information on biochips available by fol-
lowing the Chip Based & Nanovolume Biology link. The chips are a promising new
technology for sorting DNAsamples so that their nucleotide sequences can be identified.
A biochip contains an array of tiny, segregated spots, each with its own sequence of
nudeotides. The nucleotide sequences on the biochip, to which the sample DNA strands
bond, can be constructed by controlling the reagents and the amount oflight that reaches
each spot on thechip during construction. Currently, the Garnerlaboratory is experimenting
with a light processing microchip and a reagent delivery system thatwill allow the researchers
to build chips with up to 2 million unique spots. Such chips may be able to efficiendy diag-
nose geneticdiseases andidentifymedicallyrelevant genes.
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